Socioeconomic, Clinical, and Laboratory Parameters Differentiating Pediatric Patients With MOG Antibody-Associated

Brian Florenzo1, J Nicholas Brenton2

  • 1University of Virginia School of Medicine, Charlottesville, VA, USA.

Insights

Children with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) present differently than those with multiple sclerosis. MOGAD patients are younger, have lower BMIs, and are less likely to have prior Epstein-Barr virus infection.

Area of Science:

  • Pediatric Neurology
  • Immunology
  • Neuroinflammatory Diseases

Background:

  • Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) are distinct neuroinflammatory disorders.
  • While clinical and neuroimaging differences are known, socioeconomic and paraclinical distinctions in pediatric populations are less understood.

Purpose of the Study:

  • To compare socioeconomic and paraclinical characteristics of children diagnosed with MOGAD versus MS.
  • To identify key differentiating features for early diagnosis in pediatric patients.

Main Methods:

  • Retrospective study of pediatric patients (<18 years) diagnosed with MOGAD or MS.
  • Data collected included demographics, socioeconomic factors, clinical manifestations, and laboratory results.
  • Statistical analysis was performed to compare patient groups.

Main Results:

  • MOGAD patients were younger (7.6 vs 14.8 years) and had lower BMI percentiles (58th vs 83rd).
  • Mothers of MOGAD children had higher college education rates (80% vs 49%).
  • MOGAD patients were less likely to have prior Epstein-Barr virus infection (29% vs 100%) and cerebrospinal fluid oligoclonal bands (5% vs 87%).

Conclusions:

  • Pediatric MOGAD is associated with younger age, lower BMI, higher maternal education, and absence of specific biomarkers like Epstein-Barr virus infection and oligoclonal bands.
  • These findings aid in differentiating MOGAD from MS in children, offering insights into distinct pathobiology.